Navigation Links
Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
Date:2/24/2012

PITTSBURGH, Feb. 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Tony Mauro, president of Mylan North America and the company's Mylan Pharmaceuticals subsidiary, has been elected to serve as chairman of the Generic Pharmaceutical Association's (GPhA) board of directors. GPhA is an association that represents the world's leading generic drug manufacturers and suppliers. Mauro's election to this role further supports Mylan's mission to impact the future through passionate global leadership on the important issues and policies that shape the generic pharmaceuticals industry.

Mauro said: "I would like to thank the GPhA board of directors and membership for this opportunity, and also acknowledge Ralph Neas for his strong leadership of GPhA since joining the organization. I sincerely look forward to serving as chair and continuing to work closely with the board and Ralph during this truly monumental era in our industry. With growing populations, economic recessions and increasing health care costs, the need for widespread access to more affordable medicine has never been so great. The generic pharmaceutical industry, which accounts for 78% of all prescriptions dispensed in the U.S., has played an important role in saving the U.S. health care system and consumers an estimated $931 billion over the past decade."

"Generic drug makers also have stepped forward to assist the Food and Drug Administration (FDA) in addressing the industry-wide challenges, experienced by both brand and generics companies, caused by the globalization of the drug supply chain and the corresponding increase in the FDA's workload. This effort positions GPhA at the forefront of our industry's important issues, and advises policy makers that they should look to us as a key partner when tackling current and future challenges."

Mauro's term as chairman of GPhA will last for one year. Previously, he served two one-year terms as the vice chairman of the association. In his 15 years at Mylan, Mauro has held roles of increasing responsibility across the company's business units, including president of Mylan Pharmaceuticals, chief operating officer for Mylan Pharmaceuticals ULC in Canada, vice president of Strategic Development, North America, and vice president of Sales, North America.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Secures an Additional $300 Million of Committed Financing
2. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
3. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
4. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
5. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
6. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
7. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
8. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
9. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
10. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
11. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
(Date:4/19/2017)... -- Cardiology devices segment is anticipated to reach the highest ... Devices segment is likely to create absolute $ opportunity of ... 2017. By the end of 2027, Cardiology Devices segment is ... Mn, expanding at a CAGR of 18.4% over the forecast ... Pacific reprocessed medical devices market in terms of ...
(Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... RawTrition now brings you BioEnergy which is a powder ... , RawTrition is taking nutrients to the next level! The superfoods ... its raw form (unlike the synthetically made options that are on the market). , ...
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading ... patient care management module. Using this new feature, sleep physicians can now predict ... on continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea ...
Breaking Medicine News(10 mins):